Cargando…

Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?

The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zalpour, Ali, Kroll, Michael H., Afshar-Kharghan, Vahid, Yusuf, Syed Wamique, Escalante, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195274/ https://www.ncbi.nlm.nih.gov/pubmed/22013445 http://dx.doi.org/10.1155/2011/196135

Ejemplares similares

Saddle Pulmonary Embolism in a Cancer Patient with Thrombocytopenia: A Treatment Dilemma
por: Zalpour, Ali, et al.
Publicado: (2010)

Platelets in pulmonary vascular physiology and pathology
por: Kroll, Michael H., et al.
Publicado: (2012)

Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers
por: Escalante, Carmen P., et al.
Publicado: (2011)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Anticomplement therapy
por: Kulkarni, Prathit A, et al.
Publicado: (2008)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
por: Yentz, Sarah, et al.
Publicado: (2015)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Application of Molecular Modeling to Development of New Factor Xa Inhibitors
por: Sulimov, Vladimir B., et al.
Publicado: (2015)

The Development of New Factor Xa Inhibitors Based on Amide Synthesis
por: Tarasov, Dmitry N., et al.
Publicado: (2018)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Perinephric Hematoma Induced by Factor Xa Inhibitor in a Patient with a Vascular Renal Mass
por: Hussaini, Syed A., et al.
Publicado: (2020)

Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections
por: Al-Horani, Rami A.
Publicado: (2020)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients
por: Milling, Truman J., et al.
Publicado: (2021)

Roles of factor Xa beyond coagulation
por: Ruf, Wolfram
Publicado: (2021)

Cardio-Oncology: Learning From the Old, Applying to the New
por: Abe, Jun-ichi, et al.
Publicado: (2020)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

Effect of combined therapy with catheter-directed thrombolysis and factor Xa inhibitor for inferior vena cava thrombosis: A case report
por: Nonaka, Daishi, et al.
Publicado: (2018)

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis
por: Christodoulides, Alexei, et al.
Publicado: (2022)

Myocardial Infarction due to Endocarditis
por: Bathina, Jaya D., et al.
Publicado: (2011)

Any data, any time, any where
por: Malik, Sudhir
Publicado: (2013)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Less Is More: Microvascular Thrombophylaxis With Factor-Xa Inhibitor Monotherapy
por: Kotha, Vikas S., et al.
Publicado: (2019)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Factor Xa inhibitors: critical considerations for clinical development and testing
por: Becker, Richard C.
Publicado: (2021)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

The Interaction between Factor H and Von Willebrand Factor
por: Feng, Shuju, et al.
Publicado: (2013)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

Platelet activation leads to activation and propagation of the complement system
por: del Conde, Ian, et al.
Publicado: (2005)

Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases
por: Purgatorio, Rosa, et al.
Publicado: (2022)

Anti-thrombotic effect of a factor Xa inhibitor TAK-442 in a rabbit model of arteriovenous shunt thrombosis stimulated with tissue factor
por: Shinozawa, Emiko, et al.
Publicado: (2018)

SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa Inhibition
por: Strýčková, Alena, et al.
Publicado: (2022)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors
por: Terakami, Takako, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i74ldvpvf2voj6c508qrnn2sq1